238 related articles for article (PubMed ID: 35931053)
1. Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.
Brewer T; Yehia L; Bazeley P; Eng C
Am J Hum Genet; 2022 Aug; 109(8):1520-1533. PubMed ID: 35931053
[TBL] [Abstract][Full Text] [Related]
2. Integrating somatic CNV and gene expression in breast cancers from women with PTEN hamartoma tumor syndrome.
Brewer T; Yehia L; Bazeley P; Eng C
NPJ Genom Med; 2023 Jul; 8(1):14. PubMed ID: 37407629
[TBL] [Abstract][Full Text] [Related]
3. Unexpected cancer-predisposition gene variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome patients without underlying germline PTEN mutations.
Yehia L; Ni Y; Sesock K; Niazi F; Fletcher B; Chen HJL; LaFramboise T; Eng C
PLoS Genet; 2018 Apr; 14(4):e1007352. PubMed ID: 29684080
[TBL] [Abstract][Full Text] [Related]
4. WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition.
Lee YR; Yehia L; Kishikawa T; Ni Y; Leach B; Zhang J; Panch N; Liu J; Wei W; Eng C; Pandolfi PP
N Engl J Med; 2020 May; 382(22):2103-2116. PubMed ID: 32459922
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer risk and clinical implications for germline PTEN mutation carriers.
Ngeow J; Sesock K; Eng C
Breast Cancer Res Treat; 2017 Aug; 165(1):1-8. PubMed ID: 26700035
[TBL] [Abstract][Full Text] [Related]
6. Cell-free DNA fragmentomics and second malignant neoplasm risk in patients with PTEN hamartoma tumor syndrome.
Liu D; Yehia L; Dhawan A; Ni Y; Eng C
Cell Rep Med; 2024 Feb; 5(2):101384. PubMed ID: 38242121
[TBL] [Abstract][Full Text] [Related]
7. The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome.
Hoxhaj A; Drissen MMCM; Vos JR; Bult P; Mann RM; Hoogerbrugge N
Cancer; 2022 Aug; 128(15):2883-2891. PubMed ID: 36533707
[TBL] [Abstract][Full Text] [Related]
8. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
Bubien V; Bonnet F; Brouste V; Hoppe S; Barouk-Simonet E; David A; Edery P; Bottani A; Layet V; Caron O; Gilbert-Dussardier B; Delnatte C; Dugast C; Fricker JP; Bonneau D; Sevenet N; Longy M; Caux F;
J Med Genet; 2013 Apr; 50(4):255-63. PubMed ID: 23335809
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
[TBL] [Abstract][Full Text] [Related]
10. PTEN hamartoma tumour syndrome: case report based on data from the Iranian hereditary colorectal cancer registry and literature review.
Rahmatinejad Z; Goshayeshi L; Bergquist R; Goshayeshi L; Golabpour A; Hoseini B
Diagn Pathol; 2023 Apr; 18(1):43. PubMed ID: 37016356
[TBL] [Abstract][Full Text] [Related]
11. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
[TBL] [Abstract][Full Text] [Related]
12. The mitochondrial genome as a modifier of autism versus cancer phenotypes in
Wei R; Yehia L; Ni Y; Eng C
HGG Adv; 2023 Jul; 4(3):100199. PubMed ID: 37216009
[TBL] [Abstract][Full Text] [Related]
13. Soft tissue angiomatosis: another PIK3CA-related disorder.
Boccara O; Galmiche-Rolland L; Dadone-Montaudié B; Ariche-Maman S; Coulet F; Eyries M; Pannier S; Soupre V; Molina T; Pedeutour F; Fraitag S
Histopathology; 2020 Mar; 76(4):540-549. PubMed ID: 31630434
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal Analysis of Cancer Risk in Children and Adults With Germline PTEN Variants.
Yehia L; Plitt G; Tushar AM; Joo J; Burke CA; Campbell SC; Heiden K; Jin J; Macaron C; Michener CM; Pederson HJ; Radhakrishnan K; Shin J; Tamburro J; Patil S; Eng C
JAMA Netw Open; 2023 Apr; 6(4):e239705. PubMed ID: 37093598
[TBL] [Abstract][Full Text] [Related]
15. PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?
Mester JL; Moore RA; Eng C
Oncologist; 2013; 18(10):1083-90. PubMed ID: 24037976
[TBL] [Abstract][Full Text] [Related]
16. Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes.
Henderson CJ; Ngeow J; Collins MH; Martin LJ; Putnam PE; Abonia JP; Marsolo K; Eng C; Rothenberg ME
J Pediatr Gastroenterol Nutr; 2014 May; 58(5):553-60. PubMed ID: 24345843
[TBL] [Abstract][Full Text] [Related]
17. Head circumference in the clinical detection of PTEN hamartoma tumor syndrome in a clinic population at high-risk of breast cancer.
Shiovitz S; Everett J; Huang SC; Orloff MS; Eng C; Gruber SB
Breast Cancer Res Treat; 2010 Nov; 124(2):459-65. PubMed ID: 20349131
[TBL] [Abstract][Full Text] [Related]
18. Cowden syndrome.
Gustafson S; Zbuk KM; Scacheri C; Eng C
Semin Oncol; 2007 Oct; 34(5):428-34. PubMed ID: 17920899
[TBL] [Abstract][Full Text] [Related]
19. Considerations on diagnosis and surveillance measures of PTEN hamartoma tumor syndrome: clinical and genetic study in a series of Spanish patients.
Pena-Couso L; Ercibengoa M; Mercadillo F; Gómez-Sánchez D; Inglada-Pérez L; Santos M; Lanillos J; Gutiérrez-Abad D; Hernández A; Carbonell P; Letón R; Robledo M; Rodríguez-Antona C; Perea J; Urioste M;
Orphanet J Rare Dis; 2022 Feb; 17(1):85. PubMed ID: 35227301
[TBL] [Abstract][Full Text] [Related]
20. Lifetime cancer risks in individuals with germline PTEN mutations.
Tan MH; Mester JL; Ngeow J; Rybicki LA; Orloff MS; Eng C
Clin Cancer Res; 2012 Jan; 18(2):400-7. PubMed ID: 22252256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
